close

Sanofi-Aventis, a pharmaceutical company, contributes to enhancing life by providing an offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company has products in the areas of thrombosis, cardiovascular, metabolic diseases, oncology, central nervous system, internal medicine, and vaccines. Its primary medicines include Lovenox/Clexane, Plavix/Iscover, Aprovel/Avapro/Karvea, Tritace/Triatec/Delix/Altace, Lantus, Amaryl/Amarel/Solosa, Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. The company's vaccines principally include pediatric combination and poliomyelitis vaccines, influenza vaccines, meningitis/pneumonia vaccines, adult and adolescent booster vaccines, and travel and endemic vaccines. It has collaboration agreements principally with Novozymes, Dyax Corp., Oxford BioMedica, Regeneron, IDM, Zealand Pharma, UCB, and Crucell N.V., as well as partners, including Immunogen, Coley, Wayne State University, Innogenetics, and Inserm. The company also has an agreement with Drugs For Neglected Diseases Initiative (dndi) for the development, manufacturing, and distribution of fexinidazole, a drug for the treatment of human African trypanosomiasis. Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	38.51
Volume	(mio) 1.82
Volume Avg	(mio) 3.1
52 Week High	40.75
52 Week Low	30.98
PE	13.70
PE (group average)	39
EPS Year	2.82
EPS change Q/Q	177.08%
EPS change Q/Q Yr ago	-28.88%
EPS change Q/Q next Q est	-100%
EPS change Y/Y	8.64%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	4.18
Divident Annual	1.82
Dividend Yield	4.73%